End Of An Era As Generic Versions Of BMS’s Controversial Blockbuster Revlimid Arrive
Gradual Decline From $12bn Peak Expected
Revlimid was the driving force behind Celgene’s growth, but also became symbolic in the ongoing row over US drug prices.
Revlimid was the driving force behind Celgene’s growth, but also became symbolic in the ongoing row over US drug prices.